Ligand Pharmaceuticals Files 8-K for Regulation FD Disclosure
Ticker: LGNZZ · Form: 8-K · Filed: Dec 18, 2025 · CIK: 886163
| Field | Detail |
|---|---|
| Company | Ligand Pharmaceuticals Inc (LGNZZ) |
| Form Type | 8-K |
| Filed Date | Dec 18, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulation-fd, disclosure, sec-filing
Related Tickers: LGND
TL;DR
Ligand Pharma dropped an 8-K for Reg FD disclosure. Keep an eye on their news.
AI Summary
Ligand Pharmaceuticals Inc. announced on December 18, 2025, a current report filing (8-K) with the SEC. The filing pertains to Regulation FD Disclosure and was submitted from their principal executive offices in Jupiter, Florida.
Why It Matters
This filing indicates Ligand Pharmaceuticals is providing important, potentially material information to the public, ensuring fair disclosure under Regulation FD.
Risk Assessment
Risk Level: low — An 8-K filing for Regulation FD disclosure is a standard reporting requirement and does not inherently indicate increased risk.
Key Players & Entities
- LIGAND PHARMACEUTICALS INC (company) — Registrant
- December 18, 2025 (date) — Date of earliest event reported
- Jupiter, Florida (location) — Address of principal executive offices
- Regulation FD Disclosure (regulation) — Item Information
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is for Regulation FD Disclosure, ensuring timely and fair public dissemination of material information.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on December 18, 2025.
Where are Ligand Pharmaceuticals' principal executive offices located?
Ligand Pharmaceuticals' principal executive offices are located at 555 Heritage Drive, Suite 200, Jupiter, Florida 33458.
What is the company's state of incorporation?
The company's state of incorporation is Delaware.
What is the SEC file number for Ligand Pharmaceuticals?
The SEC file number for Ligand Pharmaceuticals is 001-33093.
Filing Stats: 512 words · 2 min read · ~2 pages · Grade level 13.1 · Accepted 2025-12-18 16:11:52
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share LGND The Nasdaq Global Ma
Filing Documents
- d938301d8k.htm (8-K) — 24KB
- 0001193125-25-324830.txt ( ) — 135KB
- lgnd-20251218.xsd (EX-101.SCH) — 3KB
- lgnd-20251218_lab.xml (EX-101.LAB) — 18KB
- lgnd-20251218_pre.xml (EX-101.PRE) — 11KB
- d938301d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIGAND PHARMACEUTICALS INCORPORATED Date: December 18, 2025 By: /s/ Andrew Reardon Name: Andrew Reardon Title: Chief Legal Officer and Secretary